Introduction of New Therapeutic Substances

Why This Topic Matters

The article helps readers stay current on official coding updates for new therapies and associated diagnosis terminology. That makes it relevant for accurate code maintenance, coding education, and implementation of new release guidance.

Article Sections

1. Device/Substance/Technology

   This section lists the newly added substance values associated with the ICD-10-PCS update and identifies the corresponding technology group context.

2. Brexanolone

   This section discusses the therapeutic context for brexanolone and the related procedure coding update for its administration.

3. Eladocagene Exuparvovec

   This section covers the gene therapy, the clinical setting in which it is administered, and the associated coding change. It also notes a related diagnosis code update.

4. Nerinitide

   This section summarizes the therapy’s general use and the coding update tied to its intravenous administration.

5. Durvalumab Antineoplastic

   This section describes the medication’s clinical application and the related ICD-10-PCS administration update.

6. Lefamulin Anti-infective

   This section addresses the medication’s broad use cases and the coding update for its oral and intravenous administration.

7. Mineral-based Topical Hemostatic Agent

   This section explains the general clinical context for the hemostatic agent and the associated gastrointestinal tract introduction codes.

8. Ceftolozane/Tazobactam Anti-infective

   This section summarizes the combination therapy’s broad infectious disease applications and the corresponding coding update.

9. Cefiderocol Anti-infective

   This section covers the antibacterial’s clinical use and the related intravenous administration coding change.

10. Omadacycline Anti-infective

    This section reviews the drug’s general treatment areas and the associated ICD-10-PCS administration update.

11. Eculizumab

    This section discusses the medication’s therapeutic context and the new administration coding entries.

12. Atezolizumab Antineoplastic

    This section addresses the antineoplastic drug’s general indications and the related procedure coding update.

13. Esketamine Hydrochloride

    This section explains the therapy’s clinical context and the special new technology group designation associated with its coding update.